Top January 2023 FDA Approvals
January FDA approvals include treatments for mood disorders, pertussis in infants, Alzheimer disease, and type 2 diabetes.
Diagnosis & Disease Information
FDA Accepts Resubmitted BLA for Bimekizumab for Plaque Psoriasis
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F.
Top December 2022 FDA Approvals
December FDA approvals include treatments for weight loss in adolescents, major depressive disorder, lung cancer detection, metastatic non-small cell lung cancer, multiple sclerosis, and lymphoma.
FDA Allows Certified Retail Pharmacies to Dispense Mifepristone
Mifepristone is a progestin antagonist indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.
Actemra Approved for Treatment of Hospitalized COVID-19 Patients
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
Narcan Nasal Spray Gets Priority Review for OTC Treatment of Opioid Overdose
If approved, the OTC nasal spray would deliver 4 mg of naloxone per spray.
Top Recent FDA Approvals
Recent FDA approvals include treatments for acute low back pain, postoperative nausea and vomiting, multiple myeloma, hemophilia B, and fibromyalgia pain.
Tzield Approved to Delay Onset of Stage 3 Type 1 Diabetes
Tzield is anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.
FDA Announces Adderall Shortage as Supply Decreases
Amphetamine mixed salts are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.
FDA Warns of Cybersecurity Risk With Certain Medtronic Insulin Pumps
Equipment issue may allow someone to break in and cause the pump to deliver too much or too little insulin to the patient.
- Loading...
Loading...
Next post in Practice Management Information Center
Loading... 
Loading...